Acta Scientific Nutritional Health (ASNH)(ISSN: 2582-1423)

Research Article Volume 6 Issue 12

The Impact of Ketoanalogues on Nephropathy Progression in Advanced Chronic Kidney Disease Older Patients

Gustavo Aroca-Martinez1-3, Angélica Sierra1,2, Luis Barros-Camargo4,5, Adolfo Pertuz-Pinzon4,5, Daniela Dianda2, Andrés Cadena-Bonfanti1,2 and Carlos G Musso1,6*

1Facultad de Ciencias de la Salud, Universidad Simón Bolivar, Barranquilla, Colombia
2Clínica de la Costa, Barranquilla, Colombia
3Universidad del Norte, Barranquilla, Colombia
4Universidad Libre, Barranquilla, Colombia
5Asociación Colombiana de Nefrología, Colombia
6Research Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

*Corresponding Author: Carlos G Musso, Research Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Received: October 25, 2022; Published: November 16, 2022

Abstract

Introduction: Advanced chronic kidney disease (CKD) can be treated with conservative care or renal replacement therapies. CKD is associated with an increased risk of nephropathy progression, and death. Therefore, slow down CKD progression is crucial, and there is consensus regarding protein intake regulation benefit in delaying this progression. Ketoanalogues are nitrogen-free analogs of essential amino acids which supplements low protein diets. Thus, it was decided to evaluate if keto diet had benefit in reducing CKD progression.

Material and Method: It was evaluated if there was a significant difference in CKD progression between two groups of stage 4-5 CKD patients: one group on keto diet, and one group with standard low protein diet. All patients received standard CKD treatment, and monthly eGFR (CKD-EPI) was documented. All evaluated parameters were compared between their initial and final values (delta value) in each group, and between the groups. Student and Wilcoxon tests were applied for data analysis.

Results: From 140 stage 4-5 CKD old patients, 38 patients were randomly assigned to keto diet, and the rest (n: 102) were assigned to standard reduced protein diet (control group). Both groups were followed up during 12 months. There was no significant difference between initial and final eGFR values neither in keto nor in control groups. Additionally, there was no significant difference between eGFR delta values between the two groups.

Conclusion: There was no significant eGFR in older CKD patients neither on keto diet nor on standard CKD diet.

Keywords: Chronic Kidney Disease; Ketoanalogues; Progression

References

  1. Scalone L., et al. “Cost-benefit analysis of supplemented very low-protein diet versus dialysis in elderly CKD5 patients”. Nephrology Dialysis Transplantation 25 (2010): 907-913.
  2. Perez-Gomez MV., et al. “Clarifying the concept of chronic kidney disease for non-nephrologists”. Clinical Kidney Journal2 (2019): 258-261.
  3. Musso CG and Jauregui JR. “How to differentiate renal senescence from chronic kidney disease in clinical practice”. Postgraduate Medicine 7 (2016): 716-721.
  4. Chen TK., et al. “Chronic kidney disease diagnosis and management. A Review”. JAMA 13 (2019): 1294-1304.
  5. Brunori G. “Treatment of chronic kidney disease in the elderly: diet or conservative management”. Journal of Nephrology 19 (2012): S28-S31.
  6. Musso CG., et al. “Therapeutic alternatives and palliative care for advanced renal disease in the very elderly: a review of the literature”. International Urology and Nephrology 4 (2015): 647-654.
  7. Li A., et al. “The effect of ketoanalogues on chronic kidney disease deterioration: A Meta-Analysis”. Nutrients5 (2019): 957.
  8. Bellizzi V., et al. “A Delphi consensus panel on nutritional therapy in chronic kidney disease”. Journal of Nephrology 5 (2016): 593-602.
  9. Cuppari L., et al. “A practical approach to dietary interventions for nondialysis-dependent CKD patients: The experience of a reference nephrology center in Brazil”. BMC Nephrology 1 (2016): 1-11.
  10. Sánchez C., et al. “Influence of low-protein dietetic foods consumption on quality of life and levels of B vitamins and homocysteine in patients with chronic renal failure”. Nutricion Hospitalaria 2 (2010): 238-244.
  11. Espinosa-Cuevas M and Correa-Rotter R. “[Renal alterations and Nutrition] In Arroyo, Kaufer Horowitz, Perez Lizaur (Eds)”. Nutriologia Médica. Buenos Aires. Editorial Panamericana (2015): 695-730.
  12. Bernhard J., et al. “Adaptive response to a low-protein diet in predialysis chronic renal failure patients”. Journal of the American Society of Nephrology 6 (2001): 1249-1254.
  13. Walser M and Hill S. “Can renal replacement be deferred by a supplemented very low protein diet?” Journal of the American Society of Nephrology 1 (1999): 110-116.
  14. Garneata L., et al. “SP334 Vegetarian very low protein diet supplemented with ketoanalogues may reduce nephrotic-range proteinuria in predialysis CKD patients”. Nephrology Dialysis Transplantation 1 (2016): i200-i213.
  15. Noce A., et al. “Is low-protein diet a possible risk factor of malnutrition in chronic kidney disease patients?” Cell Death Discovery 2 (2016): 16026.
  16. Fouque D and Aparicio M. “Eleven reasons to control the protein intake of patients with chronic kidney disease”. Nature Reviews Nephrology 3 (2007): 383-392.
  17. Musso CG and Macías-Núñez JF. “Renal aging and chronic kidney disease in the eldely: which are the differences?” In Musso CG, Jauregui JR, Macías-Núñez JF, Covic A (Eds). Clinical Nephrogeriatrics. An evidence-based guide. Cham. Springer (2019): 13-20.
  18. Menon V., et al. “Effect of a very low-protein diet on outcomes: Long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study”. American Journal of Kidney Diseases 53 (2009): 208-217.
  19. Malvy D., et al. “Effects of severe protein restriction with ketoanalogues in advanced renal failure”. Journal of the American College of Nutrition 18 (1999): 481-486.

Citation

Citation: Carlos G Musso., et al. “The Impact of Ketoanalogues on Nephropathy Progression in Advanced Chronic Kidney Disease Older Patients".Acta Scientific Nutritional Health 6.12 (2022): 82-87.

Copyright

Copyright: © 2022 Carlos G Musso., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.316

Indexed In





News and Events


Contact US